Welcome to our dedicated page for Procept Biorobotics news (Ticker: PRCT), a resource for investors and traders seeking the latest updates and insights on Procept Biorobotics stock.
PROCEPT BioRobotics Corporation (PRCT) delivers pioneering surgical robotics solutions for urologic care, with its AquaBeam and HYDROS systems redefining minimally invasive BPH treatment. This news hub provides investors and medical professionals with essential updates on PRCT's clinical advancements, regulatory milestones, and strategic initiatives.
Access authoritative updates including FDA clearances, peer-reviewed study results, and financial performance reports. Our curated collection features official press releases on product innovations, partnership announcements, and clinical trial outcomes backed by PRCT's extensive clinical evidence base.
Stay informed about developments in aquablation therapy technology, global market expansion efforts, and advancements in AI-driven surgical planning. Content spans regulatory filings, executive leadership updates, and analyses of PRCT's growing body of clinical validation across urologic applications.
Bookmark this page for streamlined access to PROCEPT BioRobotics' latest achievements in surgical robotics. Check regularly for verified updates on technologies improving patient outcomes through precision tissue resection and image-guided procedures.
PROCEPT BioRobotics (Nasdaq: PRCT) reported strong Q2 2025 financial results with total revenue of $79.2 million, up 48% year-over-year. The company's U.S. revenue grew 46% to $69.6 million, driven by system sales and increased handpiece revenue. International revenue surged 69% to $9.6 million.
Key highlights include 51 new U.S. robotic system sales and an expanded U.S. install base of 595 systems. Gross margin improved to 65% from 59% year-over-year. The company increased its 2025 revenue guidance to $325.5 million, representing 45% growth. Additionally, PROCEPT announced the appointment of Larry Wood as CEO, effective September 2, 2025.
PROCEPT BioRobotics (Nasdaq: PRCT) announced a significant leadership transition as CEO Dr. Reza Zadno plans to retire, with Larry L. Wood appointed as the new President and CEO effective September 2, 2025. Under Dr. Zadno's leadership since 2020, the company achieved notable milestones including successful commercialization of Aquablation® therapy, completion of its 2021 IPO, and initiation of prostate cancer clinical trials.
Mr. Wood joins from Edwards Lifesciences, bringing over 40 years of medical technology experience. The company also pre-announced strong Q2 2025 revenue of approximately $79.2 million, representing 48% annual growth. During Dr. Zadno's tenure, global Aquablation procedures grew from hundreds to nearly 100,000, with the company raising over $600M in capital.
PROCEPT BioRobotics (Nasdaq: PRCT) announced a significant milestone in its WATER IV Prostate Cancer Trial, with three successful prostate cancer procedures completed at an Ambulatory Surgery Center (ASC) using Aquablation® therapy. The procedures were performed by Dr. Rahul Mehan in Scottsdale, Arizona.
The FDA-approved IDE clinical study aims to compare Aquablation® therapy with radical prostatectomy for treating localized prostate cancer (Grade Group 1 to 3). Aquablation therapy utilizes a robotically-controlled waterjet for targeted prostate tissue removal, while radical prostatectomy involves complete prostate removal.
This milestone demonstrates the potential for treating early-stage prostate cancer in an ASC setting, suggesting a more scalable and cost-effective care model for prostate cancer treatment.
PROCEPT BioRobotics (Nasdaq: PRCT), a surgical robotics company specializing in urological solutions, has scheduled its Q2 2025 financial results announcement for August 6, 2025 after market close.
The company will host a conference call at 4:30 p.m. Eastern Time to discuss the results. Investors can access the call through a webcast link or dial-in registration for sell-side analysts. The webcast recording will be available for at least 90 days on the company's investor relations website.
PROCEPT BioRobotics (Nasdaq: PRCT) announced that its Aquablation therapy has been assigned a Category I CPT code (52XX1) effective January 1, 2026, replacing the current Category III code 0421T. The 2026 Medicare Proposed Physician Fee Schedule assigns 16.14 total RVUs to Aquablation therapy, translating to approximately $540 in national average payment, slightly higher than TURP's 15.82 RVUs ($529).
This milestone recognition reflects Aquablation therapy's clinical value and widespread adoption in BPH surgical treatment. The proposed payment rates are subject to a public comment period ending September 2025, with the Final Rule expected in November 2025.
PROCEPT BioRobotics (Nasdaq: PRCT), a surgical robotics company specializing in urology solutions, has announced its participation in four major investor conferences during May and June 2025.
The conference schedule includes:
- Bank of America Health Care Conference in Las Vegas - Fireside Chat on May 14
- William Blair Growth Stock Conference in Chicago - Presentation on June 4
- Jefferies Global Healthcare Conference in New York City - Fireside Chat on June 5
- Truist Med-Tech Conference in Boston - Fireside Chat on June 17
All events will be accessible via live webcast through the company's investor relations website, with recordings available for replay up to 90 days after each event.
PROCEPT BioRobotics (Nasdaq: PRCT) announced its participation at the 2025 American Urological Association (AUA) Annual Meeting in Las Vegas, featuring presentations on Aquablation therapy for BPH treatment. The event, taking place April 26-29, will showcase scientific presentations and interactive workshops highlighting long-term outcomes, safety, and durability of their HYDROS Robotic System.
The company's booth #1431 will host surgeon-led presentations, hands-on workshop sessions, and a dedicated resident-focused session. Notable thought leader presentations include discussions on BPH practice transformation, data-driven decisions, and optimizing BPH care pathways. The scientific program features multiple sessions on BPH surgical therapy and new technology, including the WATER IV Prostate Cancer study comparing Aquablation versus Radical Prostatectomy.
PROCEPT BioRobotics (PRCT) reported strong Q1 2025 financial results with total revenue of $69.2 million, up 55% year-over-year. The company's U.S. performance showed significant growth with handpiece and consumables revenue reaching $38.0 million (61% increase) and system revenue of $18.7 million (31% increase). International revenue doubled to $8.9 million.
The company sold 43 new robotic systems in the U.S., bringing the total U.S. install base to 547 systems. Gross margin improved to 64% compared to 56% in the prior year. Despite operating expenses increasing to $71.6 million, the net loss decreased to $24.7 million from $26.0 million year-over-year.
PROCEPT raised its 2025 revenue guidance to $323 million, representing 44% growth, and expects a full-year gross margin of approximately 64.5%.
PROCEPT BioRobotics (Nasdaq: PRCT) announced an upcoming investor event scheduled for April 25, 2025, from 8:00am to 9:30am PT at the Aria Resort in Las Vegas during the American Urological Association Annual Meeting.
The event will feature presentations from the company's leadership team, including CEO Reza Zadno, CFO Kevin Waters, CCO Sham Shiblaq, and CTO Barry Templin. Clinical perspectives will be provided by distinguished physicians: Dr. Inderbir Gill from USC Urology, Dr. Brian Helfand from Endeavor Health, and Dr. Gerald Park from Kansas City Urology Care.
The event will be accessible via live webcast on the company's investor relations website, with recordings available for at least 90 days afterward.
PROCEPT BioRobotics (NASDAQ: PRCT) announced results from the WATER III trial comparing Aquablation therapy to laser enucleation for treating large prostates (80-180mL). The international study, involving 186 men between December 2020 and September 2024, revealed that Aquablation therapy achieved similar symptom relief while demonstrating significantly better outcomes in key areas:
- Lower ejaculatory dysfunction rates (14.8% vs 77.1%)
- Lower stress incontinence rates (0% vs 9.1%)
- 0% procedural transfusion rate
The trial results, presented at the European Association of Urology 2025 Annual Congress in Madrid, add to Aquablation therapy's clinical foundation, which includes the WATER study, WATER II, and over 150 peer-reviewed publications.
FAQ
What is the current stock price of Procept Biorobotics (PRCT)?
What is the market cap of Procept Biorobotics (PRCT)?
